AddThis Social Bookmark Button

Genetic Immunity News

Genetic Immunity To Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

MCLEAN, Va. and BUDAPEST, Hungary, May 9 PRNewswire — Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be presenting at the Rodman & Renshaw 5th Annual Global Healthcare Conference to be held May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The Company's President and Chief Executive Officer, Dr. Julianna Lisziewicz, is scheduled to present an overview of the Company's clinical programs on Monday, May 19 at 9:20 a.m. CEST in the Atlantique Salon, Eastern (2nd floor).

For more information on this event please visit: http://www.rodmanandrenshaw.com/conferences.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing disease or repairing damaged tissues, such as bone, muscle, or nerve. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy approved for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.

www.geneticimmunity.com Contacts: The Ruth Group Investors Media Sara Ephraim Janine McCargo +1-646-536-7002 +1-646-536-7033 sephraim@theruthgroup.com jmccargo@theruthgroup.com

SOURCE Genetic Immunity

Send this news item to a friend.

Print This Page

Search Our News Using Google Search

Can't find what you want? Try using Google:

Google